Decreased TSP-1 following percutaneous coronary intervention is associated with major adverse cardiac events in ST-elevation myocardial infarction

Clinical Hemorheology and Microcirculation

Volumn 54, Issue 1, 2013, Pages 59-73

  Kaiser, Ralf ^a   Grotemeyer, Katharina ^a   Kälsch, Thorsten ^b   Gräber, Stefan ^a   Wilkens, Heinrike ^a   Elmas, Elif ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

major adverse cardiac events; percutaneous coronary intervention; ST elevation myocardial infarction; Thrombospondin 1

Indexed keywords

THROMBOSPONDIN 1;

ADULT; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CORONARY STENT; DISEASE ASSOCIATION; EMERGENCY TREATMENT; FEMALE; HEART DISEASE; HEART VENTRICLE FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE POOR PLASMA;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BIOLOGICAL MARKERS; CORONARY CIRCULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTORS; STENTS; TREATMENT OUTCOME;

EID: 84878845331     PISSN: 13860291     EISSN: 18758622     Source Type: Journal    
DOI: 10.3233/CH-2012-1565     Document Type: Article

References (39)

1. J. Ahamed, C. A. Janczak, K. M. Wittkowski and B. S. Coller, In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring-and shear-dependent activation of platelet-derived TGF-beta1, PLoS One 4 (2009), e6608.
2. E. M. Antman, D. T. Anbe, P. W. Armstrong, E. R. Bates, L. A. Green, M. Hand, et al. , ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction), Circulation 110 (2004), e82-e292.
3. M. Batlle, F. Perez-Villa, A. Lazaro, E. Garcia-Pras, I. Vallejos, A. Sionis, et al. , Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling, Transplant Proc 41 (2009), 2231-2233.
4. E. M. Bauer, Y. Qin, T. W. Miller, R. W. Bandle, G. Csanyi, P. J. Pagano, et al. , Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation, Cardiovasc Res 88 (2010), 471-481.
5. S. Belmadani, J. Bernal, C. C. Wei, M. A. Pallero, L. Dell'italia, J. E. Murphy-Ullrich, et al. , A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II, Am J Pathol 171 (2007), 777-789.
6. A. Bonnefoy, R. Moura and M. F. Hoylaerts, The evolving role of thrombospondin-1 in hemostasis and vascular biology, Cell Mol Life Sci 65 (2008), 713-727.
7. N. Brechot, E. Gomez, M. Bignon, J. Khallou-Laschet, M. Dussiot, A. Cazes, et al. , Modulation of macrophage activation state protects tissue from necrosis during critical limb ischemia in thrombospondin-1-deficient mice, PLoS One 3 (2008), e3950.
8. C. E. Dempfle, J. J. Kaden, K. K. Haase and M. Borggrefe, Course of indicators of thrombin activity in the early phase of acute myocardial infarction: Effect of fibrinolytic therapy and acute percutaneous coronary angioplasty, Thromb Haemost 90 (2003), 147-154.
9. E. Elmas, T. Kaelsch, C. Wolpert, T. Sueselbeck, T. Bertsch, C. E. Dempfle, et al. , Assessment of markers of thrombin generation in patients with acute myocardial infarction complicated by ventricular fibrillation, Clin Cardiol 29 (2006), 165-169.
10. Ethical guidelines for publication in Clinical Hemorheology and Microcirculation, Clin Hemorheol Microcirc 44 (2010), 1-2.
11. N. G. Frangogiannis, G. Ren, O. Dewald, P. Zymek, S. Haudek, A. Koerting, et al. , Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts, Circulation 111 (2005), 2935-2942.
12. M. Gawaz, F. J. Neumann, I. Ott, A. Schiessler and A. Schomig, Platelet function in acute myocardial infarction treated with direct angioplasty, Circulation 93 (1996), 229-237.
13. R. P. Giugliano and E. Braunwald, 2004ACC/AHA guideline for the management of patients with STEMI: The implications for clinicians, Nat Clin Pract Cardiovasc Med 2 (2005), 114-115.
14. T. Gori, Viscosity, platelet activation, and hematocrit: Progress in understanding their relationship with clinical and subclinical vascular disease, Clin Hemorheol Microcirc 49 (2011), 37-42.
15. J. S. Isenberg, Y. Jia, J. Fukuyama, C. H. Switzer, D. A. Wink and D. D. Roberts, Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake, J Biol Chem 282 (2007), 15404-15415.
16. J. S. Isenberg, J. B. Maxhimer, F. Hyodo, M. L. Pendrak, L. A. Ridnour,W. G. DeGraff, et al. , Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury, Am J Pathol 173 (2008), 1100-1112.
17. J. S. Isenberg, Y. Qin, J. B. Maxhimer, J. M. Sipes, D. Despres, J. Schnermann, et al. , Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress, Matrix Biol 28 (2009), 110-119.
18. E. A. Jaffe, J. T. Ruggiero and D. J. Falcone, Monocytes, macrophages synthesize, secrete thrombospondin, Blood 65 (1985), 79-84.
19. T. Kalsch, E. Elmas, X. D. Nguyen, N. Grebert, C. Wolpert, H. Kluter, et al. , Enhanced coagulation activation by in vitro lipopolysaccharide challenge in patients with ventricular fibrillation complicating acute myocardial infarction, J Cardiovasc Electrophysiol 16 (2005), 858-863.
20. S. Kaur,G. Martin-Manso, M. L. Pendrak, S. H. Garfield, J. S. Isenberg and D. D. Roberts, Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47, J Biol Chem 285 (2010), 38923-38932.
21. S. Kobayashi and T. Yamamoto, The molecular biologic study of the expression of thrombospondin in vascular smooth muscle cells and mesangial cells, J Diabet Complications 5 (1991), 121-123.
22. K. R. Laderoute, R. M. Alarcon, M. D. Brody, J. M. Calaoagan, E. Y. Chen, A. M. Knapp, et al. , Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor, Clin Cancer Res 6 (2000), 2941-2950.
23. J. W. Lawler, H. S. Slayter and J. E. Coligan, Isolation and characterization of a high molecular weight glycoprotein from human blood platelets, J Biol Chem 253 (1978), 8609-8616.
24. J. B. Maxhimer, H. B. Shih, J. S. Isenberg, T. W. Miller and D. D. Roberts, Thrombospondin-1/CD47 blockade following ischemia-reperfusion injury is tissue protective, Plast Reconstr Surg 124 (2009), 1880-1889.
25. T. W. Miller, J. S. Isenberg and D. D. Roberts, Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase, Br J Pharmacol 159 (2010), 1542-1547.
26. O. Mizuno,Y. Hojo, U. Ikeda,T. Katsuki, H. Fukazawa,K. Kurosaki, et al. , Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery, Am J Cardiol 85 (2000), 154-160.
27. D. F. Mosher, M. J. Doyle and E. A. Jaffe, Synthesis and secretion of thrombospondin by cultured human endothelial cells, J Cell Biol 93 (1982), 343-348.
28. M. A. Pallero, M. Talbert Roden, Y. F. Chen, P. G. Anderson, J. Lemons, B. C. Brott, et al. , Stainless steel ions stimulate increased thrombospondin-1-dependent TGF-beta activation by vascular smooth muscle cells: Implications for in-stent restenosis, J Vasc Res 47 (2010), 309-322.
29. M. W. Phelan, L. W. Forman, S. P. Perrine and D. V. Faller, Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells, J Lab Clin Med 132 (1998), 519-529.
30. V. L. Serebruany, M. G. Midei, H. Meilman, A. I. Malinin and D. R. Lowry, Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: The subset from the JUMBO study, Postgrad Med J 82 (2006), 404-410.
31. S. Sezaki, S. Hirohata, A. Iwabu, K. Nakamura, K. Toeda, T. Miyoshi, et al. , Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion, Exp Biol Med (Maywood) 230 (2005), 621-630.
32. P. Starlinger, H. P. Moll, A. Assinger, C. Nemeth, K. Hoetzenecker, B. Gruenberger, et al. , Thrombospondin-1: A unique marker to identify in vitro platelet activation when monitoring in vivo processes, J Thromb Haemost 8 (2010), 1809-1819.
33. J. Sun, B. D. Hopkins, K. Tsujikawa, C. Perruzzi, I. Adini, R. Swerlick, et al. , Thrombospondin-1 modulates VEGF-Amediated Akt signaling and capillary survival in the developing retina, Am J Physiol Heart Circ Physiol 296 (2009), H1344-H1351.
34. K. Thygesen, J. S. Alpert, H. D. White, A. S. Jaffe, F. S. Apple, M. Galvani, et al. , Universal definition of myocardial infarction, Circulation 116 (2007), 2634-2653.
35. E. J. Topol, A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes, J Am Coll Cardiol 41 (2003), S123-S129.
36. R. S. Vasan, Biomarkers of cardiovascular disease: Molecular basis and practical considerations, Circulation 113 (2006), 2335-2362.
37. Y. Xia, M. Dobaczewski, C. Gonzalez-Quesada, W. Chen, A. Biernacka, N. Li, et al. , Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism, Hypertension 58 (2011), 902-911.
38. M. Yao, D. D. Roberts and J. S. Isenberg, Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP, Pharmacol Res 63 (2011), 13-22.
39. X. Zhang, E. Galardi, M. Duquette, J. Lawler and S. Parangi, Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model, Clin Cancer Res 11 (2005), 5622-5630.